SCHEMBL470840

SCHEMBL470840

COCCN1CCNC[C@@H]1c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 1/20 0.41
CHRNB4 P30926 1/20 0.41
CHRNA3 P32297 1/20 0.41
CHRNA7 P36544 1/20 0.41
CHRNA4 P43681 1/20 0.41
KDM1A O60341 1/20 0.40
LMNA P02545 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CYP2D6 P10635 1/20 0.38
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
SLC6A3 Q01959 1/20 0.38
KMT2A Q03164 1/20 0.37
CACNA2D1 P54289 2/20 0.37
SIGMAR1 Q99720 2/20 0.37
TAAR1 Q96RJ0 1/20 0.35
LTA4H P09960 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL404339 0.84 TAAR1 (0.44) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL10409483 0.81 SLC6A2 (0.40) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL4977025 0.81 SLC18A3 (0.44) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL410563 0.80 P2RX7 (0.43) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL470870 0.80 P2RX7 (0.43) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL11712199 0.80 HRH3 (0.49) SIGMAR1
SCHEMBL27506411 0.80 TAAR1 (0.44) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL10418420 0.79 SLC18A3 (0.41) LMNASMN1; SMN2KMT2ASIGMAR1LTA4H
SCHEMBL10958845 0.78 SLC18A3 (0.39) CYP2D6SLC6A2SLC6A4SLC6A3SIGMAR1
SCHEMBL10409487 0.78 SIGMAR1 (0.39) CYP2D6SLC6A2SLC6A4SLC6A3SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2615089-B1 Pyrazoloquinoline compounds ASTELLAS PHARMA INC (JP) 2016-04-27 EP disclosed
US-8822448-B2 Pyrazoloquinoline compound ASTELLAS PHARMA INC. (JP) 2014-09-02 US disclosed
US-8822448-B2 Pyrazoloquinoline compound ASTELLAS PHARMA INC. (JP) 2014-09-02 US disclosed
US-20130225553-A1 PYRAZOLOQUINOLINE COMPOUND ASTELLAS PHARMA INC. (JP) 2013-08-29 US disclosed
US-20130225553-A1 PYRAZOLOQUINOLINE COMPOUND ASTELLAS PHARMA INC. (JP) 2013-08-29 US disclosed
WO-2012033144-A1 PYRAZOLOQUINOLINE COMPOUND アステラス製薬株式会社 (JP) 2012-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225553-A1 PYRAZOLOQUINOLINE COMPOUND PDE9A, PDE5A, PDE2A CHRNB2 3579/4885CHRNB4 3463/4885CHRNA3 3050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.